Cargando…

Combining secukinumab and apremilast to successfully treat refractory psoriatic skin and joint disease: A novel approach

Detalles Bibliográficos
Autor principal: Nisar, Muhammad K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medical Research and Education Association 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459333/
https://www.ncbi.nlm.nih.gov/pubmed/30071939
http://dx.doi.org/10.5152/eurjrheum.2018.17188
_version_ 1783410163826294784
author Nisar, Muhammad K.
author_facet Nisar, Muhammad K.
author_sort Nisar, Muhammad K.
collection PubMed
description
format Online
Article
Text
id pubmed-6459333
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Medical Research and Education Association
record_format MEDLINE/PubMed
spelling pubmed-64593332019-04-19 Combining secukinumab and apremilast to successfully treat refractory psoriatic skin and joint disease: A novel approach Nisar, Muhammad K. Eur J Rheumatol Letter to the Editor Medical Research and Education Association 2019-01 2018-04-19 /pmc/articles/PMC6459333/ /pubmed/30071939 http://dx.doi.org/10.5152/eurjrheum.2018.17188 Text en © Copyright by 2019 Medical Research and Education Association http://creativecommons.org/licenses/by-nc/4.0/ Content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
spellingShingle Letter to the Editor
Nisar, Muhammad K.
Combining secukinumab and apremilast to successfully treat refractory psoriatic skin and joint disease: A novel approach
title Combining secukinumab and apremilast to successfully treat refractory psoriatic skin and joint disease: A novel approach
title_full Combining secukinumab and apremilast to successfully treat refractory psoriatic skin and joint disease: A novel approach
title_fullStr Combining secukinumab and apremilast to successfully treat refractory psoriatic skin and joint disease: A novel approach
title_full_unstemmed Combining secukinumab and apremilast to successfully treat refractory psoriatic skin and joint disease: A novel approach
title_short Combining secukinumab and apremilast to successfully treat refractory psoriatic skin and joint disease: A novel approach
title_sort combining secukinumab and apremilast to successfully treat refractory psoriatic skin and joint disease: a novel approach
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459333/
https://www.ncbi.nlm.nih.gov/pubmed/30071939
http://dx.doi.org/10.5152/eurjrheum.2018.17188
work_keys_str_mv AT nisarmuhammadk combiningsecukinumabandapremilasttosuccessfullytreatrefractorypsoriaticskinandjointdiseaseanovelapproach